New kind of targeted drug shows promise for leukemia

11 December 2014

A new kind of cancer therapy has shown promising results for patients suffering from advanced leukemia. 

The early-phase clinical trial, led by Dr Eytan Stein, a medical oncologist at Memorial Sloan Kettering Cancer Center, found that more than half of patients involved (56 per cent) achieved complete remission after the therapy.

Around 15 per cent of patients with acute myeloid leukemia patients have a mutated form of the IDH2 gene, which is normally key for cell metabolism. However, when mutated, the gene triggers an increased production of 2-hydroxyglutarate, which prevents white blood cells from becoming infection-fighting cells. These immature cells accumulate and lead to the development of acute leukemia.

In the new study, a drug was developed to block the mutated IDH2 protein, allowing these immature white blood cells to develop normally. 

Dr Stein said traditional forms of cancer therapy kill diseased cells but have major side effects, as they can also damage healthy cells, making targeted therapies much better. He added that the new drug is "especially unique" as it targets a gene that transforms cells instead of the mutation that leads to cancer cell growth.

Overall, the study found that an additional 22 per cent of participants achieved partial remission. and 38 per cent had stable disease.

Posted by Edward Bartel

 

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Cancer

© Spire Healthcare Group plc (2016)